Cancer vaccines: will we ever learn?

References

• Smith TJ, Desch CE, David M, Somerfield MR. Would oncologists want chemotherapy if they had non-small-cell lung cancer? Oncology (Williston Park)12(3), 360, 363, 365 (1998).
   Google Scholar
• Burnet FM. The concept of immunological surveillance. Prog. Exp. Tumor Res.13, 1–27 (1970)
   PubMed Web of Science ®Google Scholar
• Coley WB. Contribution to the knowledge of sarcoma. Ann. Surg.14, 199–200 (1891).
   PubMedGoogle Scholar
• Lowy I. Experimental systems and clinical practices: tumor immunology and cancer immunotherapy, 1895–1980. J. Hist.Biol.27(3), 403–435 (1994).
   PubMed Web of Science ®Google Scholar
• Bower M, Mazhar D and Stebbing J. What’s the (end) point of cancer vaccines. Expert Rev. Anticancer Ther.6(8), 1133–1149 (2006).
   PubMed Web of Science ®Google Scholar
• Eaton JD, Perry MJA, Nicholson S et al. Allogeneic whole-cell vaccine: a Phase I/II study in men with hormone-refractory prostate cancer. BJU Int.89, 19–26 (2002).
   PubMedGoogle Scholar
• Hanna MG Jr, Hoover HC Jr, Pinedo HM, Finer M. Active specific immunotherapy with autologous tumor cell vaccines for stage II colon cancer: logistics, efficacy, safety and immunological pharmacodynamics. Hum. Vaccin.2(4), 185–191 (2006)
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Claessen AM, van Tinteren H et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial. Lancet353(9150), 345–350 (1999).
   PubMed Web of Science ®Google Scholar
• Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumor cell vaccine and risk of tumor progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomized controlled trial. Lancet363(9409), 594–599 (2004)
   PubMed Web of Science ®Google Scholar
• Doehn C, Richter A, Theodor RA et al. Prolongaion of progression-free and overall survival following adjuvant vaccination with Reniale in patients with non-metastatic renal carcinoma. Presented at: Program and Abstracts of the 27th German Cancer Congress. Berlin, Germany, 22–26 March 2006 (Abstract 395).
   Google Scholar
• Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma. Nature Med.5(10), 1171–1177 (1999).
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Gause BL, Nikcevich DA et al. Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report Clin. Lymphoma6(1), 61–64 (2005).
   PubMedGoogle Scholar
• Wierecky J, Mueller MR, Wirths S et al. Immunologic and clinical responses after vaccinations with peptide pulsed dendritic cells in metastatic renal cancer patients. Cancer Res.66(11), 5910–5918 (2006).
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Zielinski M, Linder A et al. Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J. Clin. Onc. (Meeting Abstracts)25(18 Suppl.), 7554 (2007).
   Web of Science ®Google Scholar
• Heimberger AB, Crotty LE, Archer GE et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin. Cancer Res.9, 4247–4254 (2003).
   PubMed Web of Science ®Google Scholar
• Sampson JH, Archer GE, Bigner DD et al. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 2011).
   Google Scholar
• Michael A, Ball G, Quatan N et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin. Cancer Res.11(12), 4469–4478 (2005).
   PubMed Web of Science ®Google Scholar
• Evans C, Dalgleish AG, Kumar D. Review article: immune suppression and colorectal cancer. Aliment Pharmacol. Ther.24(8), 1163–1177 (2006).
   PubMed Web of Science ®Google Scholar
• Madan RA, Gulley JL, Schlom J et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy Clin. Cancer Res.14(14), 4526–4531 (2008).
   PubMed Web of Science ®Google Scholar
• Shah RB, Mehra R, Chinnaiyan AM et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res.64(24), 9209–9216 (2004)
   PubMed Web of Science ®Google Scholar
• Gerritsen WR, van den Eertwegh AJ, de Gruijl TD et al. Expanded Phase 1 combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC). J. Clin. Oncol.26(Suppl.) (2008) (Abstract 5146).
   Google Scholar
• Chiarella P, Vulcano M, Bruzzo J et al. Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors. Cancer Immunol. Immunother.57(5), 701–718 (2008).
   Google Scholar
• Copier J, Ward S, Dalgleish AG. Cell based cancer vaccines: regulatory and commercial develoment Vaccine25(Suppl.), B35–B46 (2007).
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline Annex to Q8: Pharmaceutical Development (2007).
   Google Scholar
• Ablin RJ. Immunotherapy for prostatic cancer. Previous and prospective considerations. Oncology31(3–4), 177–202 (1975).
   PubMedGoogle Scholar
• Dalgleish AG. Cancer vaccines as a therapeutic strategy. Expert Rev. Vaccines3(6), 665–668 (2004)
   PubMedGoogle Scholar
• Morton DL. An international, randomized, Phase III trial of bacillus Calmette–Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. Presented at: 43rd American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Mulders P, Wood CG, Gorelov S et al. A multicentre, randomized, Phase III trial of a novel, autologous, therapeutic vaccine (vitespen) vs observation as adjuvant therapy in patients at high risk of recurrence after nephrectomy for renal cell carcinoma Presented at: 23rd Annual European Association of Urology Congress. Milan, Italy, 26–29 March 2008.
   Google Scholar
• Kafi K, Betting D, Yamada R, Steward K, Timmerman JM, Effect on in vivo immunogenicity of human idiotype-KLH vaccines by maleimide conjugation. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 8576).
   Google Scholar
• Levy R, Robertson MJ, Ganjoo K et al. Results of a Phase III trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin’s lymphoma (fNHL). Presented at: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research. San Diego, CA, USA, 12–16 April 2008 (Abstract LB204).
   Google Scholar